• Wondering if Mineralys Therapeutics at around US$29.35 is starting to look expensive or still offers value? This article breaks down what the current price may be implying.
• The stock has seen sharp moves recently, with a 10.1% return over the last 7 days, 3.7% over the past month, a 17.8% decline year to date, and an 88.0% return over the past year.
• Recent trading interest has been driven largely by ongoing investor focus on biotech companies that are still in the development stage and the potential impact of clinical and regulatory milestones on funding needs and dilution risk. Sector wide sentiment around early stage therapeutics has also influenced how quickly investors react to news and updated expectations for similar companies.
• Mineralys Therapeutics currently has a valuation score of 2 out of 6. Next, you will see how different valuation methods view the stock and why an even richer picture of value emerges by the end of the article.

Mineralys Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Mineralys Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes forecasts of a company’s future cash flows, then discounts them back to today using a required rate of return. The result is an estimate of what those future cash flows could be worth in today’s dollars.

For Mineralys Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $142.431 million, and analyst inputs plus Simply Wall St extrapolations project cash flows through to 2035. Within that path, projected free cash flow for 2030 is $172 million, with interim years showing both further losses and then positive cash flows as the model progresses.

When all those projected cash flows are discounted back, the estimated intrinsic value comes out to around $165.56 per share. Compared with the recent share price of about $29.35, the DCF output implies the stock is roughly 82.3% undervalued on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Mineralys Therapeutics is undervalued by 82.3%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Mineralys Therapeutics Price vs Book

For companies that are not yet profitable, valuation often shifts away from earnings-based metrics toward balance sheet-based measures. This is why the price-to-book, or P/B, ratio is useful. It compares what you pay in the market with the accounting value of net assets per share.

Growth expectations and risk still matter here. A higher P/B ratio can sometimes be associated with stronger perceived growth potential or lower perceived risk, while a lower P/B can reflect more cautious expectations or higher uncertainty about future outcomes.

Mineralys Therapeutics currently trades on a P/B ratio of 3.74x, compared with the Biotechs industry average of 2.39x and a peer average of 3.63x. Simply Wall St also provides a proprietary “Fair Ratio” for the preferred multiple, which is the P/B that would be expected given factors such as earnings growth profile, industry, profit margins, market cap and company-specific risks.

This Fair Ratio is designed to be more tailored than a simple comparison with peers or the wider industry because it adjusts for differences in growth, risk, profitability, sector and size. In the absence of a calculated Fair Ratio figure, the current P/B can only be said to sit modestly above both industry and peer benchmarks.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Mineralys Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story to your numbers by linking your view of Mineralys Therapeutics, for example whether lorundrostat’s hypertension launch is more likely to resemble the bullish US$56.00 fair value case or the bearish US$30.00 view, to explicit forecasts for future revenue, earnings and margins. You can then compare the fair value that results from that story with the current share price, with the view automatically updating as new news or earnings appear, so you can quickly see whether your chosen Narrative still justifies holding, adding or trimming the stock.

Do you think there's more to the story for Mineralys Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.